Australian consensus statement on doxycycline post‐exposure prophylaxis (doxy‐PEP) for the prevention of syphilis, chlamydia and gonorrhoea among gay, bisexual and other men who have sex with men

Abstract Introduction Doxycycline post‐exposure prophylaxis (doxy‐PEP) involves consuming 200 mg of doxycycline up to 72 hours after a condomless sex act to reduce the risk of bacterial sexually transmitted infections (STIs). Recent clinical trials of doxy‐PEP have demonstrated significant reductions in syphilis, chlamydia and, to a lesser degree, gonorrhoea among gay, bisexual and other men who have sex with men (GBMSM). There is a high level of interest in doxy‐PEP in the GBMSM community and, in response, the Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine (ASHM) held a national consensus conference with the aim of creating preliminary guidance for clinicians, community, researchers and policy makers. Main recommendations There was broad agreement that doxy‐PEP should be considered primarily for the prevention of syphilis in GBMSM who are at risk of this STI, with a secondary benefit of reductions in other bacterial STIs. At the end of the consensus process, there remained some disagreement, as some stakeholders felt strongly that doxy‐PEP should be considered only for the prevention of syphilis in GBMSM, and that the risk of increasing antimicrobial resistance outweighed any potential benefit from reductions in other bacterial STIs in the target population. The national roundtable made several other recommendations for clinicians, community, researchers and policy makers, as detailed in this article. ASHM will support the development of detailed clinical guidelines and education materials on doxy‐PEP ( www.ashm.org.au/doxy‐pep ). Changes in management as a result of this consensus statement For GBMSM at high risk of syphilis, and perhaps other bacterial STIs, clinicians may consider prescribing doxy‐PEP for a limited period of time, followed by a review of ongoing need. Unlike human immunodeficiency virus (HIV) pre‐exposure prophylaxis (PrEP), doxy‐PEP may not be suitable as a population‐level intervention and should instead be used more selectively.